Express Scripts Formulary Drops Novo Nordisk’s Victoza Based On Lack Of “Added Health Benefit”
This article was originally published in The Pink Sheet Daily
Despite its patient-friendly once-daily dosing, Novo Nordisk’s market-leading GLP-1 agonist will be dropped from the PBM’s recommended national formulary in 2014. Roughly 35 million individuals are covered by plans that adopt the Express Scripts formulary, of which a subset with type 2 diabetes may be directly impacted by the Victoza change.
You may also be interested in...
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
The tactic aims to allow the new Biden administration to scrutinize so-called “midnight rules” issued in the final days of the Trump administration before they take effect. One reg targeted by the freeze is the recent SUNSET rule from the US HHS, which would require the department and its agencies – including the FDA – to review all regulations every 10 years to determine whether they’re still necessary.